Literature DB >> 9396645

Rhinitis and inhalant allergens.

R Naclerio, W Solomon.   

Abstract

Allergic rhinitis affects about 20% of the US population. The diagnosis is based on patterns of symptoms, physical examination, and assessment of IgE antibodies by skin or in vitro testing. The most common offending allergens are pollens of grasses, trees, and weeds; fungi; animal allergens; and dust mites. In an individual with nasal allergy, exposure leads to rapid release of mast cell-derived mediators. This immediate response is followed by a cell-dominated response, including eosinophils and lymphocytes. Cytokines from T(H)2 lymphocytes, such as interleukin 4 and interleukin 5, orchestrate allergic inflammation. Resulting tissue changes produce symptoms of the disease and augment responses on subsequent exposure to allergens and irritants. Strategies for avoiding offending agents are important in management. In intermittent disease, antihistamines and/or decongestants are first prescribed. More continuous symptoms may mandate intranasal steroids. Immunotherapy is often helpful for patients who respond poorly to pharmacotherapy and avoidance.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9396645

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  3 in total

Review 1.  The pathogenesis of allergic conjunctivitis.

Authors:  A Keane-Myers
Journal:  Curr Allergy Asthma Rep       Date:  2001-11       Impact factor: 4.806

2.  Reliability assessment of the endoscopic examination in patients with allergic rhinitis.

Authors:  Georges K Ziade; Reem A Karami; Ghina B Fakhri; Elie S Alam; Abdul Latif Hamdan; Marc M Mourad; Usama M Hadi
Journal:  Allergy Rhinol (Providence)       Date:  2016-01-01

3.  The pharmacotherapy preferred by doctors in treatment of patients diagnosed with asthma or chronic obstructive pulmonary disease or allergic rhinitis and concomitant diseases: an epidemiological analysis.

Authors:  Marcin Nowak; Grzegorz Brożek; Zbigniew Doniec; Magdalena Olszanecka-Glinianowicz
Journal:  Postepy Dermatol Alergol       Date:  2017-04-13       Impact factor: 1.837

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.